NASDAQ:TWST - Twist Bioscience Stock Price, Forecast & News

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TWST stock has increased by 12.8% and is now trading at $31.82. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Twist Bioscience.

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Twist Bioscience.

Twist Bioscience Corp (NASDAQ:TWST) posted its earnings results on Thursday, February, 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.17. The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.06 million. Twist Bioscience had a negative return on equity of 86.44% and a negative net margin of 234.22%. Twist Bioscience's quarterly revenue was up 49.6% compared to the same quarter last year. View Twist Bioscience's earnings history.

Twist Bioscience issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-84 million, compared to the consensus revenue estimate of $82.52 million.

2 Wall Street analysts have issued twelve-month price objectives for Twist Bioscience's shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Twist Bioscience's stock price to reach $42.00 in the next year. This suggests a possible upside of 32.0% from the stock's current price. View analysts' price targets for Twist Bioscience.

Headlines about TWST stock have trended very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Twist Bioscience earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutTwist Bioscience.

Twist Bioscience saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,973,800 shares, an increase of 6.2% from the February 27th total of 2,800,000 shares. Based on an average daily volume of 587,700 shares, the short-interest ratio is currently 5.1 days. Approximately 21.4% of the company's shares are sold short. View Twist Bioscience's Current Options Chain.

Some companies that are related to Twist Bioscience include Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Adaptive Biotechnologies (ADPT), Audentes Therapeutics (BOLD), bluebird bio (BLUE), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Alector (ALEC), Fate Therapeutics (FATE) and Cortexyme (CRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include Amarin (AMRN), Canopy Growth (CGC), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), ProQR Therapeutics (PRQR), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Aurora Cannabis (ACB) and NovaBay Pharmaceuticals (NBY).

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Twist Bioscience's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (2.67%), Capital World Investors (1.99%), Lord Abbett & CO. LLC (1.57%), FMR LLC (1.52%), Alyeska Investment Group L.P. (1.37%) and Massachusetts Financial Services Co. MA (1.36%). Company insiders that own Twist Bioscience stock include Bill Peck, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss and William Banyai. View institutional ownership trends for Twist Bioscience.

TWST stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Barclays PLC, UBS Group AG, Windsor Creek Advisors LLC, FMR LLC, Nuveen Asset Management LLC, and Rafferty Asset Management LLC. Company insiders that have sold Twist Bioscience company stock in the last year include Bill Peck, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss, and William Banyai. View insider buying and selling activity for Twist Bioscience.

TWST stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Alyeska Investment Group L.P., ARK Investment Management LLC, Massachusetts Financial Services Co. MA, Lord Abbett & CO. LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, and Algert Global LLC. View insider buying and selling activity for Twist Bioscience.

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TWST stock can currently be purchased for approximately $31.82.

Twist Bioscience has a market capitalization of $1.13 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe. View additional information about Twist Bioscience.

The official website for Twist Bioscience is http://www.twistbioscience.com/.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]